PERSONALIS INC (PSNL)

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring...

Gapping stocks in Friday's session

Which stocks are gapping on Friday?

Stay updated with the stocks that are on the move in today's after-hours session.

Stay updated with the stocks that are on the move in today's after-hours session.

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Personalis to Participate at Upcoming Investor Conferences

Personalis Reports Third Quarter 2024 Financial Results

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis to Announce Third Quarter 2024 Financial Results

Monday Sector Laggards: Drugs, Biotechnology Stocks

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Personalis to Participate at Upcoming Investor Conferences

Why Tempus AI Stock Skyrocketed Nearly 22% Today

It deepened its involvement in a client and peer.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis and Tempus Announce Expanded Collaboration

PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q2 2024

PSNL stock results show that Personalis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Personalis (NASDAQ:PSNL) just reported results for the second quarter of 2024.P...

Personalis Reports Second Quarter 2024 Financial Results

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Personalis to Announce Second Quarter 2024 Financial Results

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)